Abstract
Collagen is the main structural protein in vertebrates. It plays an essential role in providing a scaffold for cellular support and thereby affecting cell attachment, migration, proliferation, differentiation, and survival. As such, it also plays an important role in numerous approaches to the engineering of human tissues for medical applications related to tissue, bone, and skin repair and reconstruction. Currently, the collagen used in tissue engineering applications is derived from animal tissues, creating concerns related to the quality, purity, and predictability of its performance. It also carries the risk of transmission of infectious agents and precipitating immunological reactions. The recent development of recombinant sources of human collagen provides a reliable, predictable and chemically defined source of purified human collagens that is free of animal components. The triple-helical collagens made by recombinant technology have the same amino acid sequence as human tissue-derived collagen. Furthermore, by achieving the equivalent extent of proline hydroxylation via coexpression of genes encoding prolyl hydroxylase with the collagen genes, one can produce collagens with a similar degree of stability as naturally occurring material. The recombinant production process of collagen involves the generation of single triple-helical molecules that are then used to construct more complex three-dimensional structures. If one loosely defines tissue engineering as the use of a biocompatible scaffold combined with a biologically active agent (be it a gene or gene construct, growth factor or other biologically active agent) to induce tissue regeneration, then the production of recombinant human collagen enables the engineering of human tissue based on a human matrix or scaffold. Recombinant human collagens are an efficient scaffold for bone repair when combined with a recombinant bone morphogenetic protein in a porous, sponge-like format, and when presented as a membrane, sponge or gel can serve as a basis for the engineering of skin, cartilage and periodontal ligament, depending on the specific requirements of the chosen application.
Similar content being viewed by others
Notes
The use of tradenames is for product identification purposes only and does not imply endorsement.
References
Chapekar MS. Tissue engineering: challenges and opportunities. J Biomed Mater Res 2000; 53(6): 617–20
Fox CF, Skalak R. Tissue engineering. New York: John Wiley and Sons, 1988
Godbey WT, Atala A. In vitro systems for tissue engineering. Ann N Y Acad sci 2002; 961: 10–26
Griffith LG. Emerging design principles in biomaterials and scaffolds for tissue engineering. Ann N Y Acad sci 2002; 961: 83–95
Lysaght MJ, Reyes J. The growth of tissue engineering. Tissue Eng 2001; 7 (5): 485–93
Makarand V. Tissue engineering: advances in in vitro cartilage generation. Trends Biotechnol 2002; 20(8): 351–6
Pearson RG, Bhandari R, Quirk RA, et al. Recent advances in tissue engineering: an invited review. J Long Term Eff Med Implants 2002; 12(1): 1–33
Vunjak-Novakovic G, Obradovic B, Martin I, et al. Bioreactor studies of native and tissue engineered cartilage. Biorheology 2002; 39(1-2): 259–68
Blunk T, Sieminski AL, Gooch KJ, et al. Differential effects of growth factors on tissue-engineered cartilage. Tissue Eng 2002; 8(1): 73–84
Pei M, scidel J, Vunjak-Novakovic G, et al. Growth factors for sequential cellular de- and re-differentiation in tissue engineering. Biochem Biophys Res Commun 2002; 294: 149–54
vVan Osch GJ, Mandl EW, Marijnissen WJ, et al. Growth factors in cartilage tissue engineering. Biorheology 2002; 39(1–2): 215–20
Silver FH, Pins G. Cell growth on collagen: a review of tissue engineering using scaffolds containing extracellular matrix. J Long Term Eff Med Implants 1992; 2(1): 67–80
Altman GH, Diaz F, Jakuba C, et al. Silk-based biomaterials. Biomaterials 2003; 24(3): 401–16
Altman GH, Horan RL, Lu HH, et al. Silk matrix for tissue engineered anterior cruciate ligaments. Biomaterials 2002; 23(20): 4131–41
Berisio R, Vitagliano L, Mazzarella L, et al. Recent progress on collagen triple helix structure, stability and assembly. Protein Pept Lett 2002; 9(2): 107–16
Brodsky B, Ramshaw JA. The collagen triple-helix structure. Matrix Biol 1997; 15(8-9): 545–54
Myllyharju J, Kivirikko KI. Collagens and collagen-related diseases. Ann Med 2001; 33(1): 7–21
Patino MG, Neiders ME, Andreana S, et al. Collagen: an overview. Implant Dent 2002; 11(3): 280–5
Ramshaw J, Werkmeister J, Glattauner V. Collagen-based biomaterials. Biotechol Genet Eng Rev 1996; 13: 335–82
Bateman JF, Lamandé SR, Ramshaw JAM. Collagen superfamily. In: Comper WD, editor. Extracellular matrix. Amsterdam: Harwood Academic Publishers, 1996: 22–67
Brown JC, Timpl R. The collagen superfamily. Int Arch Allergy Immunol 1995; 107(4): 484–90
Chevallay B, Herbage D. Collagen-based biomaterials as 3D scaffold for cell cultures: application for tissue engineering and gene therapy. Med Biol Eng Comput 2000; 38: 211–8
Eyre DR. Collagen: molecular diversity in the body’s protein scaffold. Science 1980; 207(4437): 1315–22
Kadler K. Extracellular matrix 1: fibril-forming collagens. Protein Profile 1995; 2 (5): 491–619
Kemp PD. Tissue engineering and cell-populated collagen matrices. Methods Mol Biol 2000; 139: 287–93
Lee CH, Singla A, Lee Y. Biomédical applications of collagen. Int J Pharm 2001; 221(1–2): 1–22
Lin CQ, Bisseil MJ. Multi-faceted regulation of cell differentiation by extracellular matrix. FASEB J 1993; 7(9): 737–43
Patino MG, Neiders ME, Andreana S, et al. Collagen as an implantable material in medicine and dentistry. J Oral Implantol 2002; 28(5): 220–5
Prockop D, Kivirikko K. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995; 64: 403–34
Ricard-Blum S, Dublet B, van der Rest M. Unconventional collagens. New York: Oxford University Press, 2000
Wong Po FC, Kaplan DL. Genetic engineering of fibrous proteins: spider dragline silk and collagen. Adv Drug Deliv Rev 2002; 54(8): 1131–43
Yang C, Li SW, Helminen HJ, et al. Apoptosis of chondrocytes in transgenic mice lacking collagen II. Exp Cell Res 1997; 235(2): 370–3
Bonnet C, Charriere G, Vaquier J, et al. Bovine collagen induced systemic symptoms: antibody formation against bovine and human collagen. J Rheumatol 1996; 23(3): 545–7
Charriere G, Bejot M, Schnitzler L, et al. Reactions to a bovine collagen implant: clinical and immunologic study in 705 patients. J Am Acad Dermatol 1989; 21(6): 1203–8
Cooperman L, Michaeli D. The immunogenicity of injectable collagen: I. A 1-year prospective study. J Am Acad Dermatol 1984; 10(4): 638–46
Meade KR, Silver FH. Immunogenicity of collagenous implants. Biomaterials 1990; 11(3): 176–80
Patino MG, Neiders ME, Andreana S, et al. Cellular inflammatory response to porcine collagen membranes. J Periodontal Res 2003; 38(5): 458–64
Asher DM. The transmissible spongiform encephalopathy agents: concerns and responses of United States regulatory agencies in maintaining the safety of biologics. Dev Biol Stand 1999; 100: 103–18
Hartmann DJ, Charriere G, Ricard-Blum S, et al. Immunogenicity of injectable collagen implants [letter]. J Dermatol Surg Oncol 1990; 16(4): 394
Hellman KB, Honstead JP, Vincent CK. Adventitious agents from animal-derived raw materials and production systems. Dev Biol Stand 1996; 88: 231–4
Miekka SI, Forng RY, Rohwer RG, et al. Inactivation of viral and prion pathogens by gamma-irradiation under conditions that maintain the integrity of human albumin. Vox Sang 2003; 84(1): 36–44
Schrieber R, Seybold U. Gelatine production, the six steps to maximum safety. Dev Biol Stand 1993; 80: 195–8
Bulleid NJ, John DC, Kadler KE. Recombinant expression systems for the production of collagen. Biochem Soc Trans 2000; 28(4): 350–3
Chapman WC, Sherman R, Boyce S. A novel collagen-based composite offers effective hemostasis for multiple surgical indications: results of a randomized controlled trial. Surgery 2001; 129(4): 445–50
Chapman WC, Wren SM, Lebovic GS, et al. Effective management of bleeding during tumor resection with a collagen-based hemostatic agent. Am Surg 2002; 68(9): 802–7
Green JG, Durham TM. Application of INSTAT hemostat in the control of gingival hemorrhage in the patient with thrombocytopenia: a case report. Oral Surg Oral Med Oral Pathol 1991; 71(1): 27–30
Kheirabadi BS, Field-Ridley A, Pearson R. Comparative study of the efficacy of the common topical hemostatic agents with fibrin sealant in a rabbit aortic anastomosis model. J Surg Res 2002; 106: 99–107
Martinez L, Ros Z, Lopez-Gutierrez JC, et al. Integra artificial dermis in pediatrie reconstructive surgery. Cir Pediatr 2002; 15(3): 97–100
Ozerdem OR, Wolfe SA, Marshall D. Use of skin substitutes in pediatrie patients. J Craniofac Surg 2003; 14(4): 517–20
Palao R, Gomez P, Huguet P. Burned breast reconstructive surgery with Integra dermal regeneration template. Br J Plast Surg 2003; 56(3): 252–9
Papp A, Harma M. A collagen based dermal substitute and the modified Meek technique in extensive burns: report of three cases. Burns 2003; 29(2): 167–71
Quarmby JW, Burnand KG, Lockhart SJM, et al. Prospective randomized trial of woven versus collagen-impregnated knitted prosthetic Dacron grafts in aortoiliac surgery. Br J Surg 1998; 85: 775–7
Sclafani AP, Romo T. Injectable fillers for facial soft tissue enhancement. Facial Plast Surg 2000; 16(1): 29–33
Wallace D, McPherson J, Ellingsworth L. In: Nimni ME, editor. Collagen. Boca Raton (FL): CRC Press, 1988: 117–44
Wisser D, Steffes J. Skin replacement with a collagen based dermal substitute, autologous keratinocytes and fibroblasts in burn trauma. Burns 2003; 29(4): 375–80
Cheng EL, Maruyama I, SundarRaj N, et al. Expression of type XII collagen and hemidesmosome-associated proteins in keratoconus corneas. Curr Eye Res 2001; 22 (5): 333–40
Vaughn PR, Galanis M, Richards KM, et al. Production of recombinant hydroxylated human type III collagen fragment in Saccharomyces cerevisiae. DNA Cell Biol 1998; 17(6): 511–8
Berisio R, Vitagliano L, Mazzarella L, et al. Crystal structure of the collagen triple helix model [(Pro-Pro-Gly)(10)](3). Protein sci 2002; 11(2): 262–70
Banyard J, Bao L, Zetter BR. Type XXIII collagen, a new transmembrane collagen identified in metastatic tumor cells. J Biol Chem 2003; 278(23): 20989–94
Boot-Handford RP, Tuckwell DS, Plumb DA, et al. A novel and highly conserved collagen (pro(alpha)1(XXVII)) with a unique expression pattern and unusual molecular characteristics establishes a new clade within the vertebrate fibrillar collagen family. J Biol Chem 2003; 278(33): 31067–77
Chanut-Delalande H, Fichard A, Bernocco S, et al. Control of heterotypic fibril formation by collagen V is determined by chain stoichiometry. J Biol Chem 2001; 276(26): 24352–9
Diab M, Wu JJ, Eyre DR. Collagen type IX from human cartilage: a structural profile of intermolecular cross-linking sites. Biochem J 1996; 314(Pt 1): 327–32
Eyre D. Collagen of articular cartilage. Arthritis Res 2002; 4(1): 30–5
Eyre DR, Wu JJ, Fernandes RJ, et al. Recent developments in cartilage research: matrix biology of the collagen II/IX/XI heterofibril network. Biochem Soc Trans 2002; 30(Pt 6): 893–9
Fernandes RJ, Schmid TM, Eyre DR. Assembly of collagen types II, IX and XI into nascent hetero-fibrils by a rat chondrocyte cell line. Eur J Biochem 2003; 270(15): 3243–50
Fertala A, Sieron AL, Ganguly A, et al. Synthesis of recombinant human procollagen II in a stably transfected tumour cell line (HT1080). Biochem J 1994; 298(Pt 1): 31–7
Fertala A, Sieron AL, Adachi E, et al. Collagen II containing a Cys substitution for Arg-alpha1-519: abnormal interactions of the mutated molecules with collagen IX. Biochemistry 2001; 40: 14422–8
Fitzgerald J, Bateman JF. A new FACIT of the collagen family: COL21 Al. FEBS Lett 2001; 505(2): 275–80
Hashimoto T, Wakabayashi T, Watanabe A, et al. CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/ collagen type XXV. EMBO J 2002; 21(7): 1524–34
Ichimura S, Wu JJ, Eyre DR. Two-dimensional peptide mapping of cross-linked type IX collagen in human cartilage. Arch Biochem Biophys 2000; 378(1): 33–9
Keizer-Gunnink I, Vuorela A, Myllyharju J, et al. Accumulation of properly folded human type III procollagen molecules in specific intracellular membranous compartments in the yeast Pichia pastoris. Matrix Biol 2000; 19(1): 29–36
Koch M, Foley JE, Hahn R, et al. Alpha l(Xx) collagen, a new member of the collagen subfamily, fibril-associated collagens with interrupted triple helices. J Biol Chem 2001; 276(25): 23120–6
Koch M, Laub F, Zhou P, et al. Collagen XXIV, a vertebrate fibrillar collagen with structural features of invertebrate collagens: selective expression in developing cornea and bone. J Biol Chem 2003; 278(44): 43236–44
Matsui Y, Wu JJ, Weis MA, et al. Matrix deposition of tryptophan-containing allelic variants of type IX collagen in developing human cartilage. Matrix Biol 2003; 22(2): 123–9
Mazzorana M, Snellman A, Kivirikko KI, et al. Involvement of prolyl 4-hydroxylase in the assembly of trimeric minicollagen XII: study in a baculovirus expression system. J Biol Chem 1996; 271(46): 29003–8
Myllyharju J, Nokelainen M, Vuorela A, et al. Expression of recombinant human type I-III collagens in the yeast Pichia pastoris. Biochem Soc Trans 2000; 28(4): 353–7
Niyibizi C, Eyre DR. Structural characteristics of cross-linking sites in type V collagen of bone: chain specificities and heterotypic links to type I collagen. Eur J Biochem 1994; 224(3): 943–50
Olsen DR, Leigh SD, Chang R, et al. Production of human type I collagen in yeast reveals unexpected new insights into the molecular assembly of collagen trimers. J Biol Chem 2001; 276(26): 24038–43
Sato K, Yomogida K, Wada T, et al. Type XXVI collagen, a new member of the collagen family, is specifically expressed in the testis and ovary. J Biol Chem 2002; 277(40): 37678–84
Toman PD, Pieper F, Sakai N, et al. Production of recombinant human type I procollagen homotrimer in the mammary gland of transgenic mice. Transgenic Res 1999; 8: 415–27
Tuckwell D. Identification and analysis of collagen alpha 1 (XXI), a novel member of the FACIT collagen family. Matrix Biol 2002; 21(1): 63–6
Klionsky D, Banta L. Intracellular sorting and processing of a yeast vacuolar hydrolase: proteinase A propeptide contains vacuolar targeting information. Mol Cell Biol 1988; 8(5): 2105–16
Vuorela A, Myllyharju J, Nissi R, et al. Assembly of human prolyl 4-hydroxylase and type III collagen in the yeast Pichia pastoris: formation of a stable enzyme tetramer requires coexpression with collagen and assembly of a stable collagen requires coexpression with prolyl 4-hydroxylase. EMBO J 1997; 16: 6702–12
Wu JJ, Eyre DR. Structural analysis of cross-linking domains in cartilage type XI collagen: insights on polymeric assembly. J Biol Chem 1995; 270(32): 18865–70
Hulmes DJ. The collagen superfamily: diverse structures and assemblies. Essays Biochem 1992; 27: 49–67
Kishore U, Reid KB. C1q: structure, function, and receptors. Immunopharmacology 2000; 49(1-2): 159–70
Trinder PK, Maeurer MJ, Brackertz D, et al. The collagen-like component of the complement system, C1q, is recognized by 7 S autoantibodies and is functionally impaired in synovial fluids of patients with rheumatoid arthritis. Immunology 1996; 87(3): 355–61
Kurata H, Cheng HM, Kozutsumi Y, et al. Role of the collagen-like domain of the human serum mannan-binding protein in the activation of complement and the secretion of this lectin. Biochem Biophys Res Commun 1993; 191(3): 1204–10
Matsushita M, Endo Y, Taira S, et al. A novel human serum lectin with collagen-and fibrinogen-like domains that functions as an opsonin. J Biol Chem 1996; 271(5): 2448–54
Eda S, Suzuki Y, Kase T, et al. Recombinant bovine conglutinin, lacking the Nterminal and collagenous domains, has less conglutination activity but is able to inhibit haemagglutination by influenza A virus. Biochem J 1996; 316(Pt 1): 43–8
Kolble K, Reid KB. The genomics of soluble proteins with collagenous domains: Clq, MBL, SP-A, SP-D, conglutinin, and CL-43. Behring Inst Mitt 1993; (93): 81–6
Reid KB, Colomb M, Petry F, et al. Complement component Cl and the collectins: first-line defense molecules in innate and acquired immunity. Trends Immunol 2002; 23(3): 115–7
McCormack FX, Whitsett JA. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J Clin Invest 2002; 109(6): 707–12
Kishore U, Reid KB. Structures and functions of mammalian collectins. Results Probl Cell Differ 2001; 33: 225–48
Reid KB. Structure/function relationships in the collectins (mammalian lectins containing collagen-like regions). Biochem Soc Trans 1993; 21(2): 464–8
Lu J, Le Y. Ficolins and the fibrinogen-like domain. Immunobiology 1998; 199(2): 190–9
Matsushita M, Fujita T. Ficolins and the lectin complement pathway. Immunol Rev 2001; 180: 78–85
Kivirikko KI. Collagen biosynthesis: a mini-review cluster. Matrix Biol 1998; 16(7): 355–6
Tandon M, Wu M, Begley TP, et al. Substrate specificity of human pro-lyl-4-hydroxylase. Bioorg Med Chem Lett 1998; 8 (10): 1139–44
Vuori K, Pihlajaniemi T, Marttila M, et al. Characterization of the human prolyl 4-hydroxylase tetramer and its multifunctional protein disulfide-isomerase subunit synthesized in a baculovirus expression system. Proc Natl Acad sci U S A 1992; 89(16): 7467–70
Rautavuoma K, Takaluoma K, Passoja K, et al. Characterization of three fragments that constitute the monomers of the human lysyl hydroxylase isoenzymes 1-3: the 30-kDa N-terminal fragment is not required for lysyl hydroxylase activity. J Biol Chem 2002; 277(25): 23084–91
Heikkinen J, Risteli M, Wang C, et al. Lysyl hydroxylase 3 is a multifunctional protein possessing collagen glucosyltransferase activity. J Biol Chem 2000; 275(46): 36158–63
Puistola U, Turpeenniemi-Hujanen TM, Myllyla R, et al. Studies on the lysyl hydroxylase reaction: II. Inhibition kinetics and the reaction mechanism. Bi-ochim Biophys Acta 1980; 611(1): 51–60
Kivirikko KI. Posttranslational Processing of Collagens. In: Bittar EE, Bittar N, editors. Principles of medical biology. Cellular organelles and the extracellular matrix. London: JAI Press, 1995: 233–54
Tuderman L, Prockop DJ. Procollagen N-proteinase: properties of the enzyme purified from chick embryo tendons. Eur J Biochem 1982; 125(3): 545–9
Csiszar K. Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucleic Acid Res Mol Biol 2001; 70: 1–33
Kagan HM, Trackman PC. Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol 1991; 5(3): 206–10
Kenyon K, Modi WS, Contente S, et al. A Novel Human cDNA with a Predicted Protein Similar to Lysyl Oxidase Maps to Chromosome 15q24-q25. J Biol Chem 1993; 268(25): 18435–7
Kim M, Otsuka M, Shimamura E, et al. The effect of L-ascorbic acid on age-related changes of pyridinoline in cartilage collagen of guinea pigs. J Nutr sci Vitaminol (Tokyo) 1998; 44(2): 217–24
Pokharna HK, Phillips FM. Collagen crosslinks in human lumbar intervertebral disc aging. Spine 1998; 23(15): 1645–8
Lauer-Fields JL, Juska D, Fields GB. Matrix metalloproteinases and collagen catabolism. Biopolymers 2002; 66(1): 19–32
Overall CM. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol 2002; 22(1): 51–86
Dung SZ. Effects of mutans streptococci, Actinomyces species and Porphyromonas gingivalis on collagen degradation. Zhonghua Yi Xue Za Zhi (Taipei) 1999; 62(11): 764–74
Hynes RO, Bader BL, Hodivala-Dilke K. Integrins in vascular development. Braz J Med Biol Res 1999; 32: 501–10
Heino J. The collagen receptor integrins have distinct ligand recognition and signaling functions. Matrix Biol 2000; 19(4): 319–23
Zhang WM, Kapyla J, Puranen JS, et al. Alpha llbeta 1 integrin recognizes the GFOGER sequence in interstitial collagens. J Biol Chem 2003; 278(9): 7270–7
Humphries M. Integrin structure. Biochem Soc Trans 2000; 28(4): 311–40
Davis GE. Affinity of integrins for damaged extracellular matrix: alpha v beta 3 binds to denatured collagen type I through RGD sites. Biochem Biophys Res Commun 1992; 182(3): 1025–31
Schwartz MA. Integrin signaling revisited. Trends Cell Biol 2001; 11(12): 466–70
Agarwal G, Kovac L, Radziejewski C, et al. Binding of discoidin domain receptor 2 to collagen I: an atomic force microscopy investigation. Biochemistry 2002; 41(37): 11091–8
Vogel WF. Collagen-receptor signaling in health and disease. Eur J Dermatol 2001; 11(6): 506–14
Koyama H, Raines EW, Bornfeldt KE, et al. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 1996; 87(6): 1069–78
Cukierman E, Pankov R, Stevens DR, et al. Taking cell-matrix adhesions to the third dimension. Science 2001; 294(5547): 1708–12
Gohari S, Gambia C, Healey M, et al. Evaluation of tissue-engineered skin (human skin substitute) and secondary intention healing in the treatment of full thickness wounds after Mohs micrographic or excisional surgery. Dermatol Surg 2002; 28(12): 1107–14
Boden SD, Zdeblick TA, Sandhu HS, et al. The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine 2000; 25(3): 376–81
Burkus JK, Transfeldt EE, Kitchel SH, et al. Clinical and radiographie outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine 2002; 27(21): 2396–408
Zyderm collagen implant, package insert [online]. Palo Alto (CA): Collagen Aesthetics (International) Ltd. Available from URL: http://www.inamed.com/products/facial/us/patient/zz/prodinfo.html [Accessed 2003 Dec 19]
Avitene (r) Microfibrillar Collagen Hemostat, package insert [online]. Woburn (MA): MedChem Products Inc. Available from URL: http://www.davol.com/HTMLFiles/Hemostasis/AviteneMicroInsert1.html [Accessed 2003 Dec 19]
Ala-Kokko L, Hyland J, Smith C, et al. Expression of a human cartilage procollagen gene (COL2A1) in mouse 3T3 cells. J Biol Chem 1991; 266(22): 14175–8
Geddis AE, Prockop DJ. Expression of human COL1A1 gene in stably transfected HT1080 cells: the production of a thermostable homotrimer of type I collagen in a recombinant system. Matrix 1993; 13(5): 399–405
Myllyharju J, Lamberg A, Notbohm H, et al. Expression of wild-type and modified proalpha chains of human type I procollagen in insect cells leads to the formation of stable [alpha1(I)]2alpha2(I) collagen heterotrimers and [al-pha1 (I)]3 homotrimers but not [alpha2(I)]3 homotrimers. J Biol Chem 1997; 272: 21824–30
Tomita M, Kitajima T, Yoshizato K. Formation of recombinant human procollagen I heterotrimers in a baculovirus expression system. J Biochem (Tokyo) 1997; 121(6): 1061–9
Veijola J, Koivunen P, Annunen P, et al. Cloning, baculovirus expression, and characterization of the alpha subunit of prolyl 4-hydroxylase from the nematode Caenorhabditis elegans: this alpha subunit forms an active alpha beta dimer with the human protein disulfide isomerase/beta subunit. J Biol Chem 1994; 269(43): 26746–53
Veijola J, Pihlajaniemi T, Kivirikko KI. Co-expression of the alpha subunit of human prolyl 4-hydroxylase with BiP polypeptide in insect cells leads to the formation of soluble and insoluble complexes: soluble alpha-subunit-BiP complexes have no prolyl 4-hydroxylase activity. Biochem J 1996; 35 (Pt 2): 613–8
de Bruin EC, Werten MWT, Laane C, et al. Endogenous prolyl 4-hydroxylation in Hansenula polymorpha and its use for the production of hydroxylated recombinant gelatin. FEMS Yeast Res 2002; 1: 291–8
Nokelainen M, Tu H, Vuorela A, et al. High-level production of human type I collagen in the yeast Pichia pastoris. Yeast 2001; 18: 797–806
Toman PD, Chisholm G, McMullin H, et al. Production of recombinant human type I procollagen trimers using a four-gene expression system in the yeast Saccharomyces cerevisiae. J Biol Chem 2000; 275(30): 23303–9
Werten MW, van den Bosch TJ, Wind RD, et al. High-yield secretion of recombinant gelatins by Pichia pastoris. Yeast 1999; 15: 1087–96
Werten MW, Wisselink WH, Jansen-van den Bosch TJ, et al. Secreted production of a custom-designed, highly hydrophilic gelatin in Pichia pastoris. Protein Eng 2001; 14(6): 447–54
John DCA, Watson A, Kind AJ, et al. Expression of an engineered form of recombinant procollagen in mouse milk. Nat Biotechnol 1999; 17: 385–9
Tomita M, Munetsuna H, Sato T, et al. Transgenic silkworms produce recombinant human type III procollagen in cocoons. Nat Biotechnol 2002; 21(1): 52–6
Yang C, Bodo M, Chang R, et al. Development of recombinant gelatin by expression of recombinant collagen in yeast and plants [abstract]. American Association of Pharmaceutical Scientists Annual Meeting and Exposition; 1999 Nov 17; New Orleans
Merle C, Perret S, Lacour T, et al. Hydroxylated human homotrimeric collagen I in Agrobacterium tumefaciens-mediated transient expression and in transgenic tobacco plant. FEBS Lett 2002; 515(1–3): 114–8
Ruggiero F, Exposito JY, Bournat P, et al. Triple helix assembly and processing of human collagen produced in transgenic tobacco plants. FEBS Lett 2000; 469: 132–6
Pihlajaniemi T, Myllyla R, Kivirikko KI. Prolyl 4-hydroxylase and its role in collagen synthesis. J Hepatol 1991; 13Suppl. 3: S2–7
Kivirikko KI, Pihlajaniemi T. Collagen hydroxylases and the protein disulfide isomerase subunit of prolyl 4-hydroxylases. Adv Enzymol Relat Areas Mol Biol 1998; 72: 325–98
Vuorela A, Myllyharju J, Pihlajaniemi T, et al. Coexpression with collagen markedly increases the half-life of the recombinant human prolyl 4-hydroxylase tetramer in the yeast Pichia pastoris. Matrix Biol 1999; 18(5): 519–22
Suzuki K. Collagen derived from a porcine skin. Fragrance J 2001; 29(11): 59–64
Olsen D, Yang C, Bodo M, et al. Recombinant collagen and gelatin for drug delivery. Adv Drug Deliv Rev 2003; 55: 1547–67
Nimni ME. Collagen: structure, function, and metabolism in normal and fibrotic tissues. Semin Arthritis Rheum 1983; 13(1): 1–86
Minamide A, Kawakami M, Hashizume H, et al. Evaluation of carriers of bone morphogenetic protein for spinal fusion. Spine 2001; 26(8): 933–9
Akamaru T, Suh D, Boden SD, et al. Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion. Spine 2003; 28(5): 429–34
Burkus JK, Dorchak JD, Sanders DL. Radiographie assessment of interbody fusion using recombinant human bone morphogenetic protein type 2. Spine 2003; 28(4): 372–7
Cornell CN, Lane JM, Chapman M, et al. Multicenter trial of Collagraft as bone graft substitute. J Orthop Trauma 1991; 5(1): 1–8
Walsh WR, Harrison J, Loefler A, et al. Mechanical and histologic evaluation of Collagraft in an ovine lumbar fusion model. Clin Orthop 2000; 375: 258–66
Tay BK, Le AX, Heilman M, et al. Use of a collagen-hydroxyapatite matrix in spinal fusion: a rabbit model. Spine 1998; 23(21): 2276–81
McPherson JM, Wallace D, Sawamura S, et al. Collagen fibrilliogenesis in vitro: a characterization of fibril quality as a function of assembly conditions. Coll Relat Res 1985; 5: 2119–35
Grabarek Z, Gergely J. Zero-length crosslinking procedure with the use of active esters. Anal Biochem 1990; 185(1): 131–5
Wong S. Chemistry of protein conjugation and crosslinking. Boca Raton (FL): CRC, 1991: 195-207
Process for fixation of calcification-resistant biological tissue. Girardot J-M, Girardot M-N, inventors; Biomédical Design, Inc., assignees. U.S. Patent No. 5,733,339. 1998 Mar 31
Method for fixation of biological tissue. Girardot, J-M, Girardot M-N, inventors; Biomedical Design, Inc, assignees. U.S. Patent No. 5,477,536 1995 Sep 5
Olde Damink LH, Dijkstra PJ, van Luyn MJ, et al. In vitro degradation of dermal sheep collagen cross-linked using a water-soluble carbodiimide. Biomaterials 1996; 17(7): 679–84
van Wachem PB, van Luyn MJ, Olde Damink LH, et al. Tissue regenerating capacity of carbodiimide-crosslinked dermal sheep collagen during repair of the abdominal wall. Int J Artif Organs 1994; 17(4): 230–9
Bellows CG, Aubin JE, Heersche JN, et al. Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif Tissue Int 1986; 38(3): 143–54
Laurencin CT, Attawia MA, Elgendy HE, et al. Tissue engineered bone-regeneration using degradable polymers: the formation of mineralized matrices. Bone 1996; 19(1 Suppl.): 93S–9S
Ali S. Matrix formation and mineralization in bone. In: Whitehead CC, editor. Bone biology and skeletal disorders in poultry. Oxford: Carfax Publishing, 1992: 19,38
Kassab MM, Cohen RE. The etiology and prevalence of gingival recession. J Am Dent Assoc 2003; 134(2): 220–5
Kassab MM, Cohen RE. Treatment of gingival recession. J Am Dent Assoc 2002; 133(11): 1499–506
Danesh-Meyer MJ, Chen ST, Rams TE. Digital subtraction radiographic analysis of GTR in human intrabony defects. Int J Periodontics Restorative Dent 2002; 22(5): 441–9
Eisig SB, Ho V, Kraut R, et al. Alveolar ridge augmentation using titanium micromesh: an experimental study in dogs. J Oral Maxillofac Surg 2003; 61(3): 347–53
Bunyaratavej P, Wang HL. Collagen membranes: a review. JPeriodontol 2001; 72(2): 215–29
Takeishi H, Irie K, Okuda K, et al. Molded bone augmentation by a combination of barrier membrane and recombinant human bone morphogenetic protein-2. Oral Dis 2001; 7(5): 281–6
Scott DL, Shipley M, Dawson A, et al. The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness. Br J Rheumatol 1998; 37(5): 546–54
Brittberg M, Tallheden T, Sjogren-Jansson B, et al. Autologous chondrocytes used for articular cartilage repair: an update. Clin Orthop 2001; 391 Suppl.: S337–48
Fuss M, Ehlers EM, Russlies M, et al. Characteristics of human chondrocytes, osteoblasts and fibroblasts seeded onto a type I/III collagen sponge under different culture conditions: a light, scanning and transmission electron microscopy study. Anat Anz 2000; 182(4): 303–10
Russlies M, Behrens P, Wunsch L, et al. A cell-seeded biocomposite for cartilage repair. Ann Anat 2002; 184(4): 317–23
Lu L, Zhu X, Valenzuela RG, et al. Biodegradable polymer scaffolds for cartilage tissue engineering. Clin Orthop 2001; 391 Suppl.: S251–70
Mast B. Wound healing: biochemical and clinical aspects. In: Cohen IK, Diegelmann RF, Lindlbad WJ, editors. The skin. Philadelphia (PA): W.B. Saunders, 2003
Bell E, Rosenberg M, Kemp P, et al. Recipes for reconstituting skin. J Biomech Eng 1991; 113(2): 113–9
Heimbach D, Luterman A, Burke J, et al. Artificial dermis for major burns: a multi-center randomized clinical trial. Ann Surg 1988; 208(3): 313–20
Yannas IV, Burke JF. Design of an artificial skin: I. Basic design principles. J Biomed Mater Res 1980; 14(1): 65–81
Bell E, Ivarsson B, Merrill C. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc Natl Acad sci U S A 1979; 76(3): 1274–8
Hayashi M, Tomita M, Yoshizato K. Production of EGF-collagen chimeric protein which shows the mitogenic activity. Biochim Biophys Acta 2001; 1528(2–3): 187–95
Acknowledgements
The work described in this review article was carried out in part with support from the National Institute of Arthritis and Musculoskeletal Diseases under grant number AR45879. The authors are employed by FibroGen Inc., a Biotechnology company developing recombinant human collagen for medical applications.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, C., Hillas, P.J., Báez, J.A. et al. The Application of Recombinant Human Collagen in Tissue Engineering. BioDrugs 18, 103–119 (2004). https://doi.org/10.2165/00063030-200418020-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00063030-200418020-00004